Provide feedbackProvide feedback

Home :: Rheumatology :: Rheumatology Conferences :: ACR 2007 Scientific Meeting

American College of Rheumatology

ACR 2007 Scientific Meeting

November 6-11, 2007Boston, MA
VerusMed is an independent news organization and is not affiliated with the American College of Rheumatology

Denosumab, certolizumab show promise as potential treatments in RA

Wednesday, December 12, 2007 | Comments

Results from trials of new therapies for the treatment of rheumatoid arthritis show that these treatments may have promise, according to experts.

Dr. Desiree van der Heijde, professor of rheumatology at the Leiden University Medical Center in the Netherlands, ...[more] Locked

Infliximab improves spinal mobility in AS, data reveal

Wednesday, December 12, 2007 | Comments

Treatment with infliximab appears to result in clinically meaningful and sustained improvements in spinal mobility among patients with ankylosing spondylitis, according to 2-year data from the ASSERT trial.

"Previous studies have shown that spinal immobility is associated with functional disability, impaired quality of ...[more] Locked

Adalimumab improves peripheral arthritis, enthesitis, axial signs, symptoms of AS in patients with long-standing disease treated in real-life practice, researchers report

Wednesday, December 12, 2007 | Comments

Adalimumab appears to improve peripheral arthritis and enthesitis as well as axial signs and symptoms in patients with active, long-standing ankylosing spondylitis, according to findings from the RHAPSODY trial.

Researchers conducted a prospective Phase IIIb trial in which 1,250 adult patients with active AS and ...[more] Locked

Rituximab efficacious in patients with inadequate response to TNF inhibitors in repeated courses

Wednesday, December 12, 2007 | Comments

Repeated courses of rituximab appear to produce sustained efficacy among patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors, according to Dr. Edward Keystone, a professor of rheumatology at the ...[more] Locked

Targeting the IL-6 cytokine pathway presents exciting opportunities in variety of disease states, experts report

Wednesday, December 12, 2007 | Comments

Interleukin-6 (IL-6) is an exciting new therapeutic target with great potential for the treatment of various inflammatory illnesses, according to a panel of experts.

The role of IL-6, which has previously been called B-cell stimulating factor, is long-recognized in the inflammatory cytokine pathway and IL-6 has greater ...[more] Locked

Abatacept improves disease activity, physical function, QOL in prior, current users of anti-TNF therapy, study data show

Wednesday, December 12, 2007 | Comments

Treatment with abatacept appears to provide clinically relevant improvements in disease activity, physical function, and health-related quality of life (HRQOL) among patients with rheumatoid arthritis who had an inadequate response to prior anti-tumor necrosis factor therapy, according to findings from the ARRIVE trial.

...[more] Locked

Adalimumab improves symptoms, patient-reported outcomes in patients with psoriasis, PsA, data show

Wednesday, December 12, 2007 | Comments

Among patients with psoriasis, treatment with adalimumab appears to improve symptoms, regardless of psoriatic arthritis (PsA) status, 16-week data suggest.

The REVEAL study was a 52-week, double-blind, Phase III trial that included 1,212 patients with moderate to severe chronic plaque psoriasis. This analysis was based on ...[more] Locked

Golimumab improves signs, symptoms, physical function among patients with AS, study data show

Wednesday, December 12, 2007 | Comments

Treatment with golimumab, a new human antibody to tumor necrosis factor, appears to improve the signs and symptoms of ankylosing spondylitis as well as physical function, study data indicate.

Researchers randomized 356 patients with definite AS to receive subcutaneous injections of golimumab in doses of 50 mg or 100 mg or ...[more] Locked

Adalimumab, etanercept safe, efficacious in long-term treatment of JRA, researchers report

Monday, November 12, 2007 | Comments

Both adalimumab and etanercept appear to be safe and highly efficacious in the long-term treatment of patients with juvenile rheumatoid arthritis (JRA), according to data from 2 studies.

Dr. Daniel Lovell, a professor of pediatrics at Cincinnati Children's Hospital Medical ...[more] Locked

Treatment expectations with TNF inhibitors

Wednesday, December 12, 2007 | Comments

The use of tumor necrosis factor inhibitors in patients with rheumatoid arthritis can help slow or prevent joint destruction, which can occur even when disease activity is low, and may increase productivity and quality of life if used appropriately, according to a panel of experts.

Clinical remission of RA in addition to ...[more] Locked

Etanercept provides sustained efficacy, improved patient-reported outcomes in AS

Wednesday, December 12, 2007 | Comments

Treatment of ankylosing spondylitis with etanercept provides sustained clinical efficacy and improvements in patient-reported outcomes throughout a 4-year period, with no new safety concerns, study data indicate.

Researchers conducted a double-blind trial in which 84 patients with active AS were randomized to receive ...[more] Locked



  1. No articles have been read
  1. No articles have been emailed
Videos